Division of WuXi PharmaTech Inc.
Latest From WuXi Biologics
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
BIO hosts summit to support collaborations on coronavirus vaccines and therapeutics, Vir advances COVID-19 antibody candidates, Gilead renounces orphan status for remdesivir, BMS joins Pfizer in pushing back investor meeting, and ASCO goes virtual.
Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations.
Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.
- Large Molecule
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Parent & Subsidiaries
- WuXi PharmaTech Inc.
- Senior Management
Zhisheng Chen, PhD, CEO
Christine Lu-Wong, EVP, CFO
Weichang Zhou, PhD, SVP, CTO
- Contact Info
Phone: 510 8183 1205
108 Meiliang Road. W
Wuxi , 214092
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.